Concepedia

Publication | Open Access

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

DOIFull Paper Access

354

Citations

21

References

2019

Year

Audrey Simonaggio, Jean‐Marie Michot, Anne Laure Voisin, Jérôme Le Pavec, Michael Collins, A. Lallart, Geoffray Cengizalp, Aurore Vozy, Ariane Laparra, Andréa Varga,
JAMA Oncology

Abstract

The risk-reward ratio for an anti-PD-1 or anti-PD-L1 rechallenge appears to be acceptable, although these patients require close monitoring; further investigation into rechallenge conditions through a prospective clinical trial is needed.

References

YearCitations

Page 1